PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-30.73%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
522.30%
G&A growth above 1.5x AVXL's 59.44%. Michael Burry would check for operational inefficiency.
No Data
No Data available this quarter, please select a different quarter.
3069944.64%
Other expenses growth while AVXL reduces costs. John Neff would investigate differences.
230.56%
Operating expenses growth while AVXL reduces costs. John Neff would investigate differences.
230.56%
Total costs growth while AVXL reduces costs. John Neff would investigate differences.
243.75%
Interest expense growth while AVXL reduces costs. John Neff would investigate differences.
418.75%
D&A growth while AVXL reduces D&A. John Neff would investigate differences.
-202.01%
EBITDA decline while AVXL shows 170.71% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-230.56%
Operating income decline while AVXL shows 7.04% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-494.03%
Other expenses reduction while AVXL shows 99.30% growth. Joel Greenblatt would examine advantage.
-176.90%
Pre-tax income decline while AVXL shows 220.04% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-100.18%
Both companies reducing tax expense. Martin Whitman would check patterns.
-176.90%
Net income decline while AVXL shows 85.09% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
89.62%
Similar EPS growth to AVXL's 86.00%. Walter Schloss would investigate industry trends.
89.62%
Similar diluted EPS growth to AVXL's 86.00%. Walter Schloss would investigate industry trends.
2567.99%
Share count reduction below 50% of AVXL's 6.65%. Michael Burry would check for concerns.
2567.99%
Diluted share reduction below 50% of AVXL's 6.65%. Michael Burry would check for concerns.